Overview

Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Treatments:
Antibodies, Monoclonal
Ipilimumab